Easier sleep management on the way with Lumryz approval

2 May 2023

A 12% jump in the stock price of Avadel Pharmaceuticals (Nasdaq: AVDL) on Monday reflects market confidence in the firm’s newly-approved cataplexy med Lumryz (sodium oxybate).

The US regulator granted approval for the extended-release formulation of sodium oxybate, which can be taken once at bedtime, improving on the twice-daily options currently available.

People with narcolepsy currently suffer from the burden of having to take a second dose in the middle of the night, and scientists at Avadel hope avoiding this could help patients to restore a more natural sleeping pattern.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK